Welcome to our dedicated page for Immuneering news (Ticker: IMRX), a resource for investors and traders seeking the latest updates and insights on Immuneering stock.
Immuneering Corporation (Nasdaq: IMRX) is a clinical-stage oncology company developing Deep Cyclic Inhibitors, with a lead focus on atebimetinib, an oral, once-daily MEK inhibitor for MAPK pathway-driven cancers such as pancreatic cancer. This news page aggregates company announcements, clinical data updates, financing news, and other disclosures that Immuneering releases through press statements and regulatory filings.
Readers can find detailed coverage of Immuneering’s clinical trial progress, including Phase 2a data for first-line pancreatic cancer patients treated with atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP). The company has reported updated overall survival, progression-free survival, response rates, and safety findings from a cohort of 34 patients, as well as case studies of patients treated with atebimetinib plus FOLFIRINOX. Immuneering also provides timelines for anticipated milestones such as additional survival data readouts and the planned initiation of a global Phase 3 registrational trial in metastatic pancreatic cancer.
In addition to clinical results, Immuneering’s news flow includes corporate and financial updates such as quarterly financial results, underwritten public offerings of Class A common stock, private placements with institutional investors, and guidance on expected cash runway. Announcements related to index inclusion, such as the company’s expected addition to the Nasdaq Biotechnology Index, and conference presentations at healthcare and scientific meetings are also part of the regular news cycle.
Investors and followers of oncology drug development can use this page to track Immuneering’s disclosures about regulatory interactions with the FDA and EMA, combination trial agreements in non-small cell lung cancer, and intellectual property developments such as the granting of a U.S. composition of matter patent for atebimetinib. Bookmark this feed to monitor how Immuneering’s Deep Cyclic Inhibitor programs and corporate strategy evolve through official company communications.
Immuneering Corporation (Nasdaq: IMRX) announced the completion of an upsized initial public offering, raising $129.4 million in gross proceeds to support its pipeline. The company expects to file an IND for IMM-1-104 in Q1 2022, targeting RAS mutant tumors. As of June 30, 2021, cash and equivalents stood at $50.2 million. R&D expenses rose to $7.0 million for Q2 2021, while net loss increased to $7.9 million or $1.61 per share, compared to the previous year. Management changes were made to strengthen leadership and expand the board.
Immuneering Corporation (Nasdaq: IMRX) announced its participation in two virtual investor conferences in September 2021. Management, including CEO Ben Zeskind and CFO Biren Amin, will discuss the company’s pipeline and business strategy. The first event is Morgan Stanley’s Global Healthcare Conference, with a presentation on September 14 at 4:15 p.m. ET. The second event is Oppenheimer's Life Sciences & Med Tech Summit, with a presentation on September 21 at 4:35 p.m. ET. Both presentations will be webcast and archived for 30 days on the company’s Investor Relations website.
Immuneering Corporation (Nasdaq: IMRX) has successfully completed its upsized initial public offering, closing on 8,625,000 shares of Class A common stock at $15.00 per share, yielding approximately $129.4 million in gross proceeds. The offering included a full exercise of the underwriters' overallotment option for 1,125,000 shares. Shares commenced trading on the Nasdaq on July 30, 2021. The funds raised are aimed at enhancing Immuneering's ongoing pipeline, which focuses on innovative oncology and neuroscience treatments.
Immuneering Corporation (Nasdaq: IMRX) announced the pricing of its upsized initial public offering (IPO) of 7,500,000 shares of Class A common stock at $15.00 per share, raising total gross proceeds of $112.5 million. The offering is expected to close on August 3, 2021. There is also a 30-day option for underwriters to purchase an additional 1,125,000 shares. Shares are set to begin trading on Nasdaq on July 30, 2021. Immuneering's pipeline focuses on oncology and neuroscience, aiming to improve patient outcomes through its unique approach in drug development.
Immuneering Corporation announces the appointment of Michael Bookman as the new General Counsel and Secretary, effective immediately. Bookman brings significant legal expertise in life sciences, previously serving as General Counsel at Frequency Therapeutics. He will support the Board in governance and legal compliance as the company advances its oncology and neuroscience drug pipeline, particularly focusing on modulating cell signaling dynamics. CEO Ben Zeskind expressed confidence in Bookman's ability to guide the company through its transition into human clinical development.